52 related articles for article (PubMed ID: 38436544)
21. PARP inhibitors in the treatment of ovarian cancer: a review.
Washington CR; Moore KN
Curr Opin Obstet Gynecol; 2021 Feb; 33(1):1-6. PubMed ID: 33369580
[TBL] [Abstract][Full Text] [Related]
22. Updates and New Options in Advanced Epithelial Ovarian Cancer Treatment.
Kurnit KC; Fleming GF; Lengyel E
Obstet Gynecol; 2021 Jan; 137(1):108-121. PubMed ID: 33278287
[TBL] [Abstract][Full Text] [Related]
23. An Overview of Ovarian Cancer: Molecular Processes Involved and Development of Target-based Chemotherapeutics.
Shaik B; Zafar T; Balasubramanian K; Gupta SP
Curr Top Med Chem; 2021; 21(4):329-346. PubMed ID: 33183204
[TBL] [Abstract][Full Text] [Related]
24. The Role of PPARs in Disease.
Wagner N; Wagner KD
Cells; 2020 Oct; 9(11):. PubMed ID: 33126411
[TBL] [Abstract][Full Text] [Related]
25. Ovarian Cancer: An Overview.
Penny SM
Radiol Technol; 2020 Jul; 91(6):561-575. PubMed ID: 32606233
[TBL] [Abstract][Full Text] [Related]
26. Targeting Cancer Stem Cells to Overcome Therapy Resistance in Ovarian Cancer.
Muñoz-Galván S; Carnero A
Cells; 2020 Jun; 9(6):. PubMed ID: 32512891
[TBL] [Abstract][Full Text] [Related]
27. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Coleman RL
Lancet Oncol; 2020 May; 21(5):710-722. PubMed ID: 32359490
[TBL] [Abstract][Full Text] [Related]
28. CTCF and CTCFL in cancer.
Debaugny RE; Skok JA
Curr Opin Genet Dev; 2020 Apr; 61():44-52. PubMed ID: 32334335
[TBL] [Abstract][Full Text] [Related]
29. Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer.
Haunschild CE; Tewari KS
Future Oncol; 2020 Mar; 16(7):225-246. PubMed ID: 31746224
[TBL] [Abstract][Full Text] [Related]
30. Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.
Gupta S; Nag S; Aggarwal S; Rauthan A; Warrier N
J Ovarian Res; 2019 Nov; 12(1):103. PubMed ID: 31685032
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of Drug Resistance in High-Grade Serous Ovarian Cancer.
Freimund AE; Beach JA; Christie EL; Bowtell DDL
Hematol Oncol Clin North Am; 2018 Dec; 32(6):983-996. PubMed ID: 30390769
[TBL] [Abstract][Full Text] [Related]
32. CRISPR-mediated deletion of prostate cancer risk-associated CTCF loop anchors identifies repressive chromatin loops.
Guo Y; Perez AA; Hazelett DJ; Coetzee GA; Rhie SK; Farnham PJ
Genome Biol; 2018 Oct; 19(1):160. PubMed ID: 30296942
[TBL] [Abstract][Full Text] [Related]
33. Risk-Associated Long Noncoding RNA FOXD3-AS1 Inhibits Neuroblastoma Progression by Repressing PARP1-Mediated Activation of CTCF.
Zhao X; Li D; Huang D; Song H; Mei H; Fang E; Wang X; Yang F; Zheng L; Huang K; Tong Q
Mol Ther; 2018 Mar; 26(3):755-773. PubMed ID: 29398485
[TBL] [Abstract][Full Text] [Related]
34. YY1 Is a Structural Regulator of Enhancer-Promoter Loops.
Weintraub AS; Li CH; Zamudio AV; Sigova AA; Hannett NM; Day DS; Abraham BJ; Cohen MA; Nabet B; Buckley DL; Guo YE; Hnisz D; Jaenisch R; Bradner JE; Gray NS; Young RA
Cell; 2017 Dec; 171(7):1573-1588.e28. PubMed ID: 29224777
[TBL] [Abstract][Full Text] [Related]
35. How to Combine ChIP with qPCR.
Asp P
Methods Mol Biol; 2018; 1689():29-42. PubMed ID: 29027162
[TBL] [Abstract][Full Text] [Related]
36. The CCCTC-binding factor (CTCF)-forkhead box protein M1 axis regulates tumour growth and metastasis in hepatocellular carcinoma.
Zhang B; Zhang Y; Zou X; Chan AW; Zhang R; Lee TK; Liu H; Lau EY; Ho NP; Lai PB; Cheung YS; To KF; Wong HK; Choy KW; Keng VW; Chow LM; Chan KK; Cheng AS; Ko BC
J Pathol; 2017 Dec; 243(4):418-430. PubMed ID: 28862757
[TBL] [Abstract][Full Text] [Related]
37. Depletion of CTCF in Breast Cancer Cells Selectively Induces Cancer Cell Death via p53.
Lee JY; Mustafa M; Kim CY; Kim MH
J Cancer; 2017; 8(11):2124-2131. PubMed ID: 28819414
[TBL] [Abstract][Full Text] [Related]
38. Functional roles of CTCF in breast cancer.
Oh S; Oh C; Yoo KH
BMB Rep; 2017 Sep; 50(9):445-453. PubMed ID: 28648147
[TBL] [Abstract][Full Text] [Related]
39. CTCF cooperates with noncoding RNA MYCNOS to promote neuroblastoma progression through facilitating MYCN expression.
Zhao X; Li D; Pu J; Mei H; Yang D; Xiang X; Qu H; Huang K; Zheng L; Tong Q
Oncogene; 2016 Jul; 35(27):3565-76. PubMed ID: 26549029
[TBL] [Abstract][Full Text] [Related]
40. Ribosomal proteins: functions beyond the ribosome.
Zhou X; Liao WJ; Liao JM; Liao P; Lu H
J Mol Cell Biol; 2015 Apr; 7(2):92-104. PubMed ID: 25735597
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
